We 'don't know a lot' about motor neurone disease. This is what advocates say needs to change
One of them is 41-year-old Canberra mother Sharon, who is confined to a wheelchair.
She started noticing a slight limp and other minor issues with her right leg and foot when she was playing netball. Within six months of being diagnosed in 2018 she started using a walker for short distances and a scooter for longer distances. She later had a feeding tube inserted and transitioned to using a wheelchair. "MND impacts every part of my body and every aspect of my life, but I'm just as intelligent and switched on as I've ever been," she said. The mother of two of boys communicates using an eye-gaze technology machine which converts pre-recorded sentences into words. She has documented her journey on social media.
"MND is not an incurable disease, we just haven't found the cure yet."
Former AFL great Neale Daniher has campaigned for more MND research since being diagnosed. More research needs to be done and consolidated through a national database on the causes of the disease, MND Australia CEO Clare Sullivan said. "It's one of those diseases we still don't know a lot about, there's no specific diagnosis," she told AAP. "You have to exclude everything else, and then you're left with motor neurone disease. "That also goes to why we need better data. We don't even know how many people in Australia have motor neurone disease."
It's estimated that it affects about one in 10,000 people with about 2,700 people in the country battling the degenerative condition, according to official figures extrapolated from different sources.
The average life expectancy for a person diagnosed with MND is between two to three years. In a report published by the peak body earlier this year, it put the cost of the devastating disease at about $4.85 billion based on lost productivity, the unpaid carer burden and direct healthcare system costs. "As a country, we can be much more empathetic and inclusive of people with disabilities," Sullivan said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
SBS Australia
41 minutes ago
- SBS Australia
NITV Radio News - 28/07/2025
NITV Radio brings the latest in the News, sport and weather. The federal government is being urged to increase its funding for global health research to better anticipate and prepare for climate-related health issues, antimicrobial resistance and future pandemics. A new report has found one in five Australian households are struggling to pay their energy bills, with renters more heavily affected. Victorian Labor members plan to use this weekend's state conference to demand the federal government move to immediately recognise a Palestinian state. That and more in the program for NITV Radio.
News.com.au
2 hours ago
- News.com.au
AFL and Carlton player Zac Williams signs up to become a registered organ donor after finding out his wife already was
Zac Williams has kicked plenty of goals in his career as an AFL star. But a recent shift off the field has lead him to quite a different goal in his personal life. After a converstaion with wife Rachel Lucas, the Carlton Football player has signed up as a registered organ donor with DonateLife. 'I'm probably one of those people that have been oblivious for so long about organ donation,' Williams told Lucas, a former Ballerina, was already a registered organ donor and helped encourage the former GWS Giant to do the same, along with other family and close friends. 'It was actually a very passionate conversation that we had about it,' Williams said. 'Hearing stories from people that have received organ donations and how it saved their lives, was really inspirational. 'I was pretty easily convinced that if you become an organ donor how much you can help others.' The pair, who married in 2024 share two children, son Beckham and daughter Ayla. Williams' decision to register as a donor comes as the median time people currently on the kidney transplant wait list has risen to 2.6 years. The waiting period is dependant on individual's blood type and location, but is significantly higher than the average wait time for a liver transplant which is eight to 12 months. More than 200 Australians have died in the past five years waiting for a transplant, but there are concerns the figure may actually be higher as patients are removed from waitlists as they're conditions worsen. Williams is speaking ahead of DonateLife Week which aims to raise national awareness about organ and tissue donation between July 27 and August 3. Williams even let his good friend and rival AFL player from Port Adelaide Jeremy Finlayson know he'd made the move. Finlayson's wife Kellie was diagnosed with Stage four bowel cancel at 25 years old in 2021, after giving birth to their daughter Sophia just three months prior. Not long later in 2022 after experiencing shortness of breath, it was confirmed the disease had spread to her colon. Kellie has been receiving blood from donors helping save her life following surgeries and ongoing treatment. Williams meanwhile is facing a tough uphill battle with a struggling Carlton side that have slumped to 12th in this season's standings. The 2013 AFL rising star has seen a positional shift at times and has been a consistent member of the squad.
News.com.au
3 hours ago
- News.com.au
Health Check: Clarity shares surge after ‘fast and sizeable' $203m raise
• Clarity Pharmaceuticals rocket up to 12% after its blitzkrieg placement • Artrya, Botanix and Imricor are among today's quarterly updates • Lumos outlines US market potential Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) has surprised investors with a monstrous $203 million institutional placement, struck at a 15% premium to the company's 15-day average price. None will be more surprised than the short sellers, who account for close to 10% of the company's register. Executive chairman Dr Alan Taylor says the 'fast, well executed and sizeable' placement was to a small group of local instos 'close to the company'. Unusually, no-one blabbed and the shares did not enter trading halt. 'I have never done a deal that fast,' Taylor told Stockhead. 'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group . "The raising was struck at $4.20 a share, a 2.2% premium to Friday's close and a hefty 18% more than the 15-day weighted average price. The raising comes amid what Taylor dubs 'an incredibly tumultuous' period driven by US politics, as well as some 'unfortunate news' from local biotechs (read: Opthea's (ASX:OPT) phase III trial failure). In December Clarity shares were promoted to the ASX200, which was good for enhancing Clarity's profile. But it also contributed to shorting activity. Given the share gains, these investors are likely to be buying up stock to cover their positions. Well funded for trials Clarity emerges from the raising with $288 million of cash, which will fund the company's packed slate of trials. These include two phase III prostate cancer imaging trial aimed at US Food & Drug Administration registration, dubbed Amplify and Clarify. Amplify is for patients with biochemical recurrence post treatment; Clarify is for those intended to undertake prostate removal. Both are open label and single-arm (with no placebo and comparison cohort). Another trial on the sidelines, Co-PSMA compares Clarity's tool with the standard-of-care diagnosis methods. The company expects an initial data readout on this one before the end of the year, with Amplify and Clarify readouts next year. Clarity listed in August 2021, raising a record $92 million at $1.40 apiece. The company then went one better in April last year, raising $121 million in a right issue and placement (at $2.55 a share). The raising is one of the biggest in biotech history and the chunkiest since Mesoblast gathered $260 million in a placement in January. Imricor confident of US approval Imricor Medical Systems (ASX:IMR) is confident of US approval of its world-first ablation catheter this year. We say 'world's first' because the device is the only one capable of being guided by magnetic resonance imaging (MRI), as opposed to x-ray fluoroscopy. Imricor's submission is by way of a staggered, modular process. The company reports the second module is under review and the company expects to submit the third module in the December quarter. 'We expect a steady string of 510(k) product submissions and approvals , which in turn helps accelerate the commercial launch across the US," the company says. In the March quarter European regulators approved Vision-MR, the company's updated catheter for type 1 atrial flutter, under the Continent's bolstered Medical Devices Regulation. In the June quarter they also gave the nod to Advantage-MR, which enables a physician to use a recording system and cardiac stimulator while ablating. The European gatekeepers also approved Northstar, 'the world's only MRI-native 3D mapping and guidance system.' With June quarter receipts of US$85,000, Imricor is yet to start European sales in earnest. The company posted June quarter outflows of US$4.43 million, taking cash on hand to a handy US$50.3 million. Sales will flow this quarter, says plaque-buster Artrya Still on matters of the heart, Artrya (ASX:AYA) expects first US subscription revenue from its AI-enabled Salix coronary plaque detection platform in the current quarter. An algorithm-based artificial intelligence tool, Salix detects the plaque deposits on x-ray coronary computed tomography angiograph (CCTA) images. Despite vulnerable plaque being the cause of most heart attacks, plaque currently is not routinely reported in cardiac imaging and diagnostics. It's difficult to detect with the naked eye in traditional images. In March the FDA approved Salix Coronary Anatomy (SCA) and Artrya is now seeking the agency's consent for Salix Coronary Plaque (SCP). SCP expands applicability to detecting and quantifying coronary arterial plaque for those patients who have undergone a coronary CT angiogram. The SCP module will integrate automatically with SCA. SCA already is being trialled and in clinical use, by Artrya's customers and partners, generating a symbolic $8000 in receipts of the quarter. Earlier this month Artrya inked its first commercial deal, a five-year minimum $600,000 contract with Tanner Health. Artrya expended $5.44 million for the quarter, taking cash to $11.3 million. The company expects a $4.5-5 million R&D tax refund by the end of the year. Botanix reports 600% revenue uptick Botanix Pharmaceuticals (ASX:BOT) reports net revenue of $4.3 million from US sales of Sofdra, compared with $700,000 in the March quarter. The company launched the drug – which treat an excessive sweating condition – in the US in March quarter. The 'net' descriptor is relevant, because some folks were taken aback after the company's July 8 update which showed the extent to which other parties clipped the revenue ticket, Doctors wrote 7053 prescriptions during the quarter, 324% higher than 2975 in the March stanza. The number of prescribers rose 11%, to 2316 from 1075 previously. Launching a drug is not cheap and the company burnt $28.4 million, leaving cash of $64.9 million. Let's be CLIA, it's a big market says Lumos Lumos Diagnostics (ASX:LDX) expects its Febridx virus-versus-bacterial diagnostic tool to capture eight million US patients within three years, via its company making distribution deal with Phase Scientific. Announcing the tie up on July 16, Lumos said the deal would deliver US$2 million immediately – cash the company has, indeed, banked – and a total of US$317 million ($487 million) over six years. Detailing the arrangement on Friday, CEO Doug Ward said the company expected a total addressable market of 80 million, assuming the FDA grants a so-called CLIA waiver. The number consists of patients present with acute respiratory infections. 'Our thinking is that in years two to three we will be 2% or 3% of that,' Ward said. 'In year six, that ramps up to 10%.' As in Clinical Laboratories Improvement Act, CLIA requires hospitals and labs to operate under government accreditation Exemption from CLIA enables parties such as GPs and medical assistants to carry out the low-complexity lateral-flow assays. In financial terms, the market increases tenfold, to US$1 billion a year. Lumos is carrying out a trial to support its FDA application and has recruited close to 120 of the bacterial-positive patients required. Coming back to the finances, Phase pays Lumos another US$1.5 million on its CLIA application, expected next month. On FDA approval, Phase pays another US$5 million. That leaves US$308 million over years three to six, which Ward says is based on minimum order volumes. Lumos shares rocketed 133% on the back of the Phase announcement and have held their gains.
